Latest Guidance News

Echelon Resources has completed the Palm Valley 14 appraisal well as a gas producer after a flow test recorded approximately 3 million standard cubic feet per day with no water or oil. First gas is expected before the end of October, with the well forecast to deliver 3-4 terajoules a day once tied in.

Orcoda has expanded workforce volumes under its Wagner and Wellcamp agreement, generating approximately $2.35 million in revenue during the September quarter. The facility is now being scaled towards its current capacity of 1,000 workers per day.

Fortescue shipped 46.8 million tonnes of iron ore in the September quarter, down 6% from a year earlier, while sales lagged production amid negotiations with China Mineral Resources Group. Net debt also rose to US$2.8 billion after the final dividend and quarterly capital spending, although FY27 guidance remains unchanged.

Trajan Scientific and Medical (ASX:TRJ) says FY27 has begun with improving revenue, quarterly nEBITDA of about A$3.5 million and a A$1.6 million reduction in net debt. The company expects mid-single-digit organic revenue growth and double-digit nEBITDA growth for the year, although its latest quarterly figures remain unaudited.

Servcorp Limited (ASX:SRV) has posted a third consecutive record year, with underlying profit, free cash flow and dividends all rising sharply. The debt-free workspace operator is guiding to another year of strong cash generation while investing in Saudi Arabia, technology and AI-enabled services.

InFocus is extending its Codexa platform from US sweepstakes gaming into licensed real-money online gambling markets, initially targeting Curaçao and crypto-native operators. Commercial availability is expected in early 2027, but the expansion still depends on product testing, regulatory registration and customer uptake.

Ramelius Resources produced 48,839 ounces in the September quarter and generated A$60.2 million in underlying free cash flow, keeping it on track for FY27 guidance. The gold miner also ended the period with A$768.0 million in cash and gold after progressing its Mt Magnet expansion, Rebecca-Roe approvals and share buyback.

Noxopharm says the FDA has supported its proposed Phase II design and chemical manufacturing strategy for SOF-SKN, its topical treatment candidate for cutaneous lupus erythematosus. The feedback improves regulatory clarity, but the trial remains targeted for the first half of calendar 2028 and is subject to further studies and regulatory requirements.

West African Resources produced a record 127,950 ounces of gold in the September quarter, keeping its 2026 guidance within reach. Strong output at Kiaka offset weaker Sanbrado production, although explosives permitting remains an unresolved operational constraint.

Tāiko Critical Minerals has submitted its response to Expert Panel comments on the Southern Block of its Barrytown project, with the approval decision still scheduled for 8 December. The company says it has met every deadline so far, but the filing does not indicate whether consent will be granted.

West Wits Mining has received a second R236 million senior debt drawdown, taking total funding received for Qala Shallows to R575 million and supporting its claim that the project is funded through steady-state production. Underground development is accelerating, with stoping scheduled to begin in February 2027 and annual recovered gold targeted at 70,000 ounces by early 2029.

SKS Technologies’ Jinks family has sold 10 million shares in an on-market crossing, but will retain about 21% of the company and says no further sales are planned for the foreseeable future. The company also reaffirmed FY27 expectations of approximately $500 million in revenue and $60 million in PBT.